Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial

Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial

The Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes trial showed no incremental benefit of extended-release niacin (ERN) therapy added to simvastatin in subjects with cardiovascular disease (CVD). To examine the effects of ERN...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical lipidology 2018-03, Vol.12 (2), p.348-355.e2
Hauptverfasser: Otvos, James D., Guyton, John R., Connelly, Margery A., Akapame, Sydney, Bittner, Vera, Kopecky, Steven L., Lacy, Megan, Marcovina, Santica M., Muhlestein, Joseph B., Boden, William E.
Format: Artikel
Sprache:eng
Schlagworte:
Cardiovascular disease
GlycA
Lipoprotein particles
Nuclear magnetic resonance spectroscopy
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 355.e2
container_issue 2
container_start_page 348
container_title Journal of clinical lipidology
container_volume 12
creator Otvos, James D.
Guyton, John R.
Connelly, Margery A.
Akapame, Sydney
Bittner, Vera
Kopecky, Steven L.
Lacy, Megan
Marcovina, Santica M.
Muhlestein, Joseph B.
Boden, William E.
description The Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes trial showed no incremental benefit of extended-release niacin (ERN) therapy added to simvastatin in subjects with cardiovascular disease (CVD). To examine the effects of ERN treatment on lipoprotein particles and GlycA, a new marker of systemic inflammation, and their relations with incident CVD events including mortality. GlycA and very low–density lipoprotein, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) particle subclasses were quantified by nuclear magnetic resonance spectroscopy using available stored baseline (n = 2754) and 1-year in-trial (n = 2581) samples. Associations with CVD events and all-cause mortality were assessed using multivariable Cox proportional hazards regression adjusted for age, sex, diabetes, treatment assignment, and lipoproteins. Compared to placebo, ERN treatment lowered very low–density lipoprotein and LDL and increased HDL particle concentrations, increased LDL and HDL particle sizes (all P 
doi_str_mv 10.1016/j.jacl.2018.01.002
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5931743</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1933287418300229</els_id><sourcerecordid>1999199505</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-8d0a81954825bf82ee93686ce98617dd45c5b8472d1d4d0b875e086eb85aa0bc3</originalsourceid><addsrcrecordid>eNp9kc-KFDEQxoMo7h99AQ-So5fuTdKd7kREGBadGVgRRM8hndQ4GTKdNkmPzCv41GZ21kUvHkIF6vu-KuqH0CtKakpod7Ord9r4mhEqakJrQtgTdElF31VtL-TT8pdNUzHRtxfoKqUdIZz3hD9HF0y2RPZMXKJfX8Dr7MKYcNjgpT-aBdajxd5NYYohgxvxpGN2xgNO85AmMA4S_unyFhsdrQsHnczsdcRwgDGne_s-xKy9y8e3eIGnkDLeBlM62h-Tux-Vt4AX60_Var1c4Ryd9i_Qs432CV4-1Gv07eOHr7er6u7zcn27uKtMy3muhCVaUMlbwfiwEQxANp3oDEjR0d7alhs-iLZnltrWkkH0HIjoYBBcazKY5hq9P-dO87AHa8rSUXs1RbfX8aiCdurfzui26ns4KC4b2rdNCXjzEBDDjxlSVnuXDHivRwhzUlRKWR4nvEjZWWpiSCnC5nEMJeoEUe3UCaI6QVSEqgKxmF7_veCj5Q-1Inh3FkA508FBVKlAGQ1YF8FkZYP7X_5vf5Swuw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1999199505</pqid></control><display><type>article</type><title>Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial</title><source>Access via ScienceDirect (Elsevier)</source><creator>Otvos, James D. ; Guyton, John R. ; Connelly, Margery A. ; Akapame, Sydney ; Bittner, Vera ; Kopecky, Steven L. ; Lacy, Megan ; Marcovina, Santica M. ; Muhlestein, Joseph B. ; Boden, William E.</creator><creatorcontrib>Otvos, James D. ; Guyton, John R. ; Connelly, Margery A. ; Akapame, Sydney ; Bittner, Vera ; Kopecky, Steven L. ; Lacy, Megan ; Marcovina, Santica M. ; Muhlestein, Joseph B. ; Boden, William E.</creatorcontrib><description>The Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes trial showed no incremental benefit of extended-release niacin (ERN) therapy added to simvastatin in subjects with cardiovascular disease (CVD). To examine the effects of ERN treatment on lipoprotein particles and GlycA, a new marker of systemic inflammation, and their relations with incident CVD events including mortality. GlycA and very low–density lipoprotein, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) particle subclasses were quantified by nuclear magnetic resonance spectroscopy using available stored baseline (n = 2754) and 1-year in-trial (n = 2581) samples. Associations with CVD events and all-cause mortality were assessed using multivariable Cox proportional hazards regression adjusted for age, sex, diabetes, treatment assignment, and lipoproteins. Compared to placebo, ERN treatment lowered very low–density lipoprotein and LDL and increased HDL particle concentrations, increased LDL and HDL particle sizes (all P &lt; .0001), but did not affect GlycA. Baseline and in-trial GlycA levels were associated with increased risk of CVD events: hazard ratio (HR) per SD increment, 1.17 (95% confidence interval [CI], 1.06–1.28) and 1.13 (1.02–1.26), respectively. However, none of the lipoprotein particle classes or subclasses was associated with incident CVD. By contrast, all-cause mortality was significantly associated with both GlycA (baseline HR: 1.46 [1.22–1.75]; in-trial HR: 1.41 [1.24–1.60]) and low levels of small HDL particles (baseline HR: 0.69 [0.56–0.86]; in-trial HR: 0.69 [0.56–0.86]). This Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes trial post hoc substudy indicates that inflammation, as indexed by GlycA, is unaffected by ERN treatment but is significantly associated with the residual risk of CVD and death in patients treated to low levels of LDL cholesterol. •GlycA is a novel nuclear magnetic resonance–derived biomarker of systemic inflammation.•Niacin does not alter GlycA levels.•Low LDL levels achieved in the AIM-HIGH trial facilitate study of residual risk.•GlycA was significantly associated with residual cardiovascular risk in AIM-HIGH.•Mortality was predicted by GlycA (directly) and small HDL particles (inversely).</description><identifier>ISSN: 1933-2874</identifier><identifier>EISSN: 1876-4789</identifier><identifier>DOI: 10.1016/j.jacl.2018.01.002</identifier><identifier>PMID: 29409728</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Cardiovascular disease ; GlycA ; Lipoprotein particles ; Nuclear magnetic resonance spectroscopy</subject><ispartof>Journal of clinical lipidology, 2018-03, Vol.12 (2), p.348-355.e2</ispartof><rights>2018 National Lipid Association</rights><rights>Copyright © 2018 National Lipid Association. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-8d0a81954825bf82ee93686ce98617dd45c5b8472d1d4d0b875e086eb85aa0bc3</citedby><cites>FETCH-LOGICAL-c455t-8d0a81954825bf82ee93686ce98617dd45c5b8472d1d4d0b875e086eb85aa0bc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jacl.2018.01.002$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29409728$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Otvos, James D.</creatorcontrib><creatorcontrib>Guyton, John R.</creatorcontrib><creatorcontrib>Connelly, Margery A.</creatorcontrib><creatorcontrib>Akapame, Sydney</creatorcontrib><creatorcontrib>Bittner, Vera</creatorcontrib><creatorcontrib>Kopecky, Steven L.</creatorcontrib><creatorcontrib>Lacy, Megan</creatorcontrib><creatorcontrib>Marcovina, Santica M.</creatorcontrib><creatorcontrib>Muhlestein, Joseph B.</creatorcontrib><creatorcontrib>Boden, William E.</creatorcontrib><title>Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial</title><title>Journal of clinical lipidology</title><addtitle>J Clin Lipidol</addtitle><description>The Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes trial showed no incremental benefit of extended-release niacin (ERN) therapy added to simvastatin in subjects with cardiovascular disease (CVD). To examine the effects of ERN treatment on lipoprotein particles and GlycA, a new marker of systemic inflammation, and their relations with incident CVD events including mortality. GlycA and very low–density lipoprotein, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) particle subclasses were quantified by nuclear magnetic resonance spectroscopy using available stored baseline (n = 2754) and 1-year in-trial (n = 2581) samples. Associations with CVD events and all-cause mortality were assessed using multivariable Cox proportional hazards regression adjusted for age, sex, diabetes, treatment assignment, and lipoproteins. Compared to placebo, ERN treatment lowered very low–density lipoprotein and LDL and increased HDL particle concentrations, increased LDL and HDL particle sizes (all P &lt; .0001), but did not affect GlycA. Baseline and in-trial GlycA levels were associated with increased risk of CVD events: hazard ratio (HR) per SD increment, 1.17 (95% confidence interval [CI], 1.06–1.28) and 1.13 (1.02–1.26), respectively. However, none of the lipoprotein particle classes or subclasses was associated with incident CVD. By contrast, all-cause mortality was significantly associated with both GlycA (baseline HR: 1.46 [1.22–1.75]; in-trial HR: 1.41 [1.24–1.60]) and low levels of small HDL particles (baseline HR: 0.69 [0.56–0.86]; in-trial HR: 0.69 [0.56–0.86]). This Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes trial post hoc substudy indicates that inflammation, as indexed by GlycA, is unaffected by ERN treatment but is significantly associated with the residual risk of CVD and death in patients treated to low levels of LDL cholesterol. •GlycA is a novel nuclear magnetic resonance–derived biomarker of systemic inflammation.•Niacin does not alter GlycA levels.•Low LDL levels achieved in the AIM-HIGH trial facilitate study of residual risk.•GlycA was significantly associated with residual cardiovascular risk in AIM-HIGH.•Mortality was predicted by GlycA (directly) and small HDL particles (inversely).</description><subject>Cardiovascular disease</subject><subject>GlycA</subject><subject>Lipoprotein particles</subject><subject>Nuclear magnetic resonance spectroscopy</subject><issn>1933-2874</issn><issn>1876-4789</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kc-KFDEQxoMo7h99AQ-So5fuTdKd7kREGBadGVgRRM8hndQ4GTKdNkmPzCv41GZ21kUvHkIF6vu-KuqH0CtKakpod7Ord9r4mhEqakJrQtgTdElF31VtL-TT8pdNUzHRtxfoKqUdIZz3hD9HF0y2RPZMXKJfX8Dr7MKYcNjgpT-aBdajxd5NYYohgxvxpGN2xgNO85AmMA4S_unyFhsdrQsHnczsdcRwgDGne_s-xKy9y8e3eIGnkDLeBlM62h-Tux-Vt4AX60_Var1c4Ryd9i_Qs432CV4-1Gv07eOHr7er6u7zcn27uKtMy3muhCVaUMlbwfiwEQxANp3oDEjR0d7alhs-iLZnltrWkkH0HIjoYBBcazKY5hq9P-dO87AHa8rSUXs1RbfX8aiCdurfzui26ns4KC4b2rdNCXjzEBDDjxlSVnuXDHivRwhzUlRKWR4nvEjZWWpiSCnC5nEMJeoEUe3UCaI6QVSEqgKxmF7_veCj5Q-1Inh3FkA508FBVKlAGQ1YF8FkZYP7X_5vf5Swuw</recordid><startdate>20180301</startdate><enddate>20180301</enddate><creator>Otvos, James D.</creator><creator>Guyton, John R.</creator><creator>Connelly, Margery A.</creator><creator>Akapame, Sydney</creator><creator>Bittner, Vera</creator><creator>Kopecky, Steven L.</creator><creator>Lacy, Megan</creator><creator>Marcovina, Santica M.</creator><creator>Muhlestein, Joseph B.</creator><creator>Boden, William E.</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180301</creationdate><title>Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial</title><author>Otvos, James D. ; Guyton, John R. ; Connelly, Margery A. ; Akapame, Sydney ; Bittner, Vera ; Kopecky, Steven L. ; Lacy, Megan ; Marcovina, Santica M. ; Muhlestein, Joseph B. ; Boden, William E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-8d0a81954825bf82ee93686ce98617dd45c5b8472d1d4d0b875e086eb85aa0bc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Cardiovascular disease</topic><topic>GlycA</topic><topic>Lipoprotein particles</topic><topic>Nuclear magnetic resonance spectroscopy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Otvos, James D.</creatorcontrib><creatorcontrib>Guyton, John R.</creatorcontrib><creatorcontrib>Connelly, Margery A.</creatorcontrib><creatorcontrib>Akapame, Sydney</creatorcontrib><creatorcontrib>Bittner, Vera</creatorcontrib><creatorcontrib>Kopecky, Steven L.</creatorcontrib><creatorcontrib>Lacy, Megan</creatorcontrib><creatorcontrib>Marcovina, Santica M.</creatorcontrib><creatorcontrib>Muhlestein, Joseph B.</creatorcontrib><creatorcontrib>Boden, William E.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical lipidology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Otvos, James D.</au><au>Guyton, John R.</au><au>Connelly, Margery A.</au><au>Akapame, Sydney</au><au>Bittner, Vera</au><au>Kopecky, Steven L.</au><au>Lacy, Megan</au><au>Marcovina, Santica M.</au><au>Muhlestein, Joseph B.</au><au>Boden, William E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial</atitle><jtitle>Journal of clinical lipidology</jtitle><addtitle>J Clin Lipidol</addtitle><date>2018-03-01</date><risdate>2018</risdate><volume>12</volume><issue>2</issue><spage>348</spage><epage>355.e2</epage><pages>348-355.e2</pages><issn>1933-2874</issn><eissn>1876-4789</eissn><abstract>The Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes trial showed no incremental benefit of extended-release niacin (ERN) therapy added to simvastatin in subjects with cardiovascular disease (CVD). To examine the effects of ERN treatment on lipoprotein particles and GlycA, a new marker of systemic inflammation, and their relations with incident CVD events including mortality. GlycA and very low–density lipoprotein, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) particle subclasses were quantified by nuclear magnetic resonance spectroscopy using available stored baseline (n = 2754) and 1-year in-trial (n = 2581) samples. Associations with CVD events and all-cause mortality were assessed using multivariable Cox proportional hazards regression adjusted for age, sex, diabetes, treatment assignment, and lipoproteins. Compared to placebo, ERN treatment lowered very low–density lipoprotein and LDL and increased HDL particle concentrations, increased LDL and HDL particle sizes (all P &lt; .0001), but did not affect GlycA. Baseline and in-trial GlycA levels were associated with increased risk of CVD events: hazard ratio (HR) per SD increment, 1.17 (95% confidence interval [CI], 1.06–1.28) and 1.13 (1.02–1.26), respectively. However, none of the lipoprotein particle classes or subclasses was associated with incident CVD. By contrast, all-cause mortality was significantly associated with both GlycA (baseline HR: 1.46 [1.22–1.75]; in-trial HR: 1.41 [1.24–1.60]) and low levels of small HDL particles (baseline HR: 0.69 [0.56–0.86]; in-trial HR: 0.69 [0.56–0.86]). This Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes trial post hoc substudy indicates that inflammation, as indexed by GlycA, is unaffected by ERN treatment but is significantly associated with the residual risk of CVD and death in patients treated to low levels of LDL cholesterol. •GlycA is a novel nuclear magnetic resonance–derived biomarker of systemic inflammation.•Niacin does not alter GlycA levels.•Low LDL levels achieved in the AIM-HIGH trial facilitate study of residual risk.•GlycA was significantly associated with residual cardiovascular risk in AIM-HIGH.•Mortality was predicted by GlycA (directly) and small HDL particles (inversely).</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>29409728</pmid><doi>10.1016/j.jacl.2018.01.002</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1933-2874
ispartof Journal of clinical lipidology, 2018-03, Vol.12 (2), p.348-355.e2
issn 1933-2874
1876-4789
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5931743
source Access via ScienceDirect (Elsevier)
subjects Cardiovascular disease
GlycA
Lipoprotein particles
Nuclear magnetic resonance spectroscopy
title Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T02%3A42%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Relations%20of%20GlycA%20and%20lipoprotein%20particle%20subspecies%20with%20cardiovascular%20events%20and%20mortality:%20A%20post%20hoc%20analysis%20of%20the%20AIM-HIGH%20trial&rft.jtitle=Journal%20of%20clinical%20lipidology&rft.au=Otvos,%20James%20D.&rft.date=2018-03-01&rft.volume=12&rft.issue=2&rft.spage=348&rft.epage=355.e2&rft.pages=348-355.e2&rft.issn=1933-2874&rft.eissn=1876-4789&rft_id=info:doi/10.1016/j.jacl.2018.01.002&rft_dat=%3Cproquest_pubme%3E1999199505%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1999199505&rft_id=info:pmid/29409728&rft_els_id=S1933287418300229&rfr_iscdi=true